Subject(s)
Acidosis/etiology , Diagnostic Errors/prevention & control , Drug Overdose , Ibuprofen , Nonprescription Drugs , Peptic Ulcer/etiology , Acidosis/physiopathology , Adult , Analgesics, Opioid/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Back Pain/drug therapy , Codeine/administration & dosage , Drug Combinations , Drug Labeling , Drug Overdose/diagnosis , Drug Overdose/etiology , Drug Overdose/physiopathology , Female , Humans , Ibuprofen/administration & dosage , Ibuprofen/adverse effects , Middle Aged , Nonprescription Drugs/administration & dosage , Nonprescription Drugs/adverse effects , Opioid-Related Disorders/complications , Peptic Ulcer/physiopathologyABSTRACT
Two hundred twenty-three patients were enrolled on this randomized Phase III trial testing the value of late consolidative involved-field radiation therapy in the treatment of limited-stage small cell lung cancer (SCLC). Patients were treated with induction chemotherapy consisting of alternating cycles of procarbazine, vincristine, lomustine, and cyclophosphamide (POCC) and etoposide, doxorubicin, and methotrexate (VAM) for 6 to 9 months. Responding patients were then randomized at 6 or 9 months to chemotherapy alone or to involved-field radiation therapy. All partial and complete responders received prophylactic cranial irradiation. Of the 180 eligible and evaluable patients, 80 (44%) achieved a complete response and 39 (22%) achieved a partial response (overall rate of response, 66%). Actuarial median survival time was 11.6 months, with 16% of patients surviving 2 years and 11% surviving 5 years. Forty-eight patients were randomized to chemotherapy alone (24 patients) versus chemotherapy plus involved-field radiation therapy (24 patients). There were no significant differences in time to progression or survival between those patients receiving or not receiving involved-field radiation therapy. The thorax was the site of first relapse in 58% of patients randomized to chemotherapy alone versus 29% in patients randomized to chemotherapy plus involved-field radiation therapy (P equals 0.042). The major acute toxicity was reversible myelosuppression, and the major late toxicity was chronic central nervous system dysfunction. The authors conclude that the addition of late consolidative radiation therapy to induction chemotherapy in the treatment of limited-stage SCLC is well tolerated and improves local control, but does not improve time to progression or rates of survival.
Subject(s)
Carcinoma, Small Cell/radiotherapy , Lung Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Combined Modality Therapy , Female , Follow-Up Studies , Humans , Lung Neoplasms/drug therapy , Male , Middle Aged , Radiotherapy/adverse effectsABSTRACT
Between October 1985 and March 1987, 92 patients were registered on a phase II study of the Northern California Oncology Group investigating the importance of dose intensity in the treatment of advanced non-small cell lung cancer (NSCLC). Treatment consisted of high-dose cisplatin in hypertonic saline (200 mg/m2 on a 28-day cycle) given in a divided day 1 and day 8 schedule. The response rate among 76 assessable patients was 36% (27/76), with complete response (CR) in 8% (6/76) and partial response (PR) in 28% (21/76). If all patients receiving any drug therapy were considered, the overall response rate was 31% (27/87), with CR in 7% (6/87) and PR in 24% (21/87). Median survival times for all assessable patients and all patients receiving any therapy were 37 and 35 weeks, respectively. With the use of a protocol design specifying dose delays rather than dose reduction for toxicity, the mean dose intensity delivered was 47.2 mg/m2 per week, or 94% of projected. Compared with other dose-intensive regimens of cisplatin, this day 1 and day 8 schedule was relatively well tolerated, with peripheral neuropathy as the dose-limiting toxicity. The data on response and median survival times among patients receiving this single-agent therapy are encouraging. They support the potential importance of cisplatin dose intensity in the treatment of NSCLC. Whether these results represent a positive dose-response effect in NSCLC will be tested in a randomized comparative trial of high-dose versus standard-dose cisplatin therapy.
Subject(s)
Carcinoma, Non-Small-Cell Lung/drug therapy , Cisplatin/administration & dosage , Lung Neoplasms/drug therapy , Adenocarcinoma/drug therapy , Adult , Aged , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Small Cell/drug therapy , Carcinoma, Squamous Cell/drug therapy , Cisplatin/adverse effects , Drug Administration Schedule , Drug Evaluation , Female , Humans , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Male , Middle Aged , Peripheral Nervous System Diseases/chemically induced , Peripheral Nervous System Diseases/pathologyABSTRACT
Between 1978 and 1984, the Northern California Oncology Group (NCOG) conducted a randomized trial to study the efficacy of combined radiotherapy (RT) and chemotherapy (CT) for stage III or IV inoperable head and neck cancer. One hundred four patients were randomized to receive: (1) RT alone, or (2) RT plus CT. RT consisted of 7,000 cGy to the involved areas and 5,000 cGy to uninvolved neck at 180 cGy/fraction, five fractions/wk. CT consisted of bleomycin, 5 U intravenously (IV), twice weekly during RT, followed by bleomycin, 15 U IV, and methotrexate, 25 mg/m2 IV weekly for 16 weeks after completion of RT. Fifty-one patients in the RT alone group and 45 in the combined treatment group were evaluable. The local-regional complete response (CR) rate was 45% v 67% (P = .056); the 2-year local-regional control rate, including salvage surgery, was 26% v 64% (P = .001); and the incidence of distant metastasis was 24% v 38% (P greater than .25), for the RT alone and RT plus CT groups, respectively. The relapse-free survival curves were significantly different (P = .041), favoring the combined treatment. However, the survival curves were not significantly different (P = .16). Patient compliance to maintenance CT was poor. Bleomycin significantly increased the acute radiation mucositis, although the difference in late normal tissue toxicity was not statistically significant. Thus, bleomycin and concurrent RT produced a more favorable CR rate, local-regional control rate, and relapse-free survival, but the difference in survival was not statistically significant.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bleomycin/administration & dosage , Head and Neck Neoplasms/radiotherapy , Methotrexate/administration & dosage , Adult , Aged , Aged, 80 and over , Clinical Trials as Topic , Combined Modality Therapy , Female , Head and Neck Neoplasms/drug therapy , Humans , Male , Middle Aged , Random AllocationABSTRACT
Forty-four adult patients with lymphoblastic lymphoma (LBL) were treated according to one of two protocols. Both included (1) induction with cyclophosphamide, doxorubicin, vincristine, prednisone, and L-asparaginase; (2) CNS prophylaxis; and (3) maintenance therapy with methotrexate (MTX) and 6-mercaptopurine. In the second protocol, CNS prophylaxis began earlier than in the first protocol and included cranial irradiation and intrathecal (IT) MTX rather than simultaneous high-dose systemic and IT MTX. The overall response rate was 100% (95% complete). With a 26-month median follow-up, the 1-and 3-year actuarial freedom from relapse (FFR) for the composite patient group was 70% and 56%, respectively. The incidence of CNS relapse was reduced from 31% in the first protocol to 3% in the second protocol (P = .04, Gehan). Patients can be assigned retrospectively to low (n = 19) and high (n = 25) risk prognostic groups, as indicated by a multivariate analysis of pretreatment prognostic factors. High-risk is defined by Ann Arbor stage IV disease with bone marrow or CNS involvement or initial serum lactate dehydrogenase (LDH) concentration of greater than 300 IU/L (normal, less than 200). FFR of low- and high-risk groups at 5 years are 94% and 19%, respectively (P = .0006). Low-risk patients are highly curable using this approach to adult LBL. More intensive treatment for high-risk patients is warranted.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lymphoma, Non-Hodgkin/drug therapy , Adult , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Brain Neoplasms/pathology , Drug Administration Schedule , Female , Humans , L-Lactate Dehydrogenase/blood , Lymphoma, Non-Hodgkin/pathology , Lymphoma, Non-Hodgkin/radiotherapy , Male , Neoplasm Staging , Phenotype , Prognosis , Risk , Spinal Cord Diseases/pathologyABSTRACT
We report the efficacy and toxicity of combined cisplatin, methotrexate and vinblastine for the treatment of metastatic transitional cell carcinoma of the bladder in 50 evaluable patients. Of these 50 patients 17 had not undergone cystectomy and had residual invasive bladder cancer. Of these 17 patients 11 had complete response of the bladder lesions following cisplatin, methotrexate and vinblastine for metastatic disease, including 6 of 12 treated by cisplatin, methotrexate and vinblastine alone, and 5 of 5 treated with cisplatin, methotrexate and vinblastine plus palliative or preoperative pelvic irradiation. Complete response was confirmed in 10 of the 11 patients by endoscopy and biopsy, and in 1 by cystectomy. One patient whose liver metastasis responded to cisplatin, methotrexate and vinblastine had conversion to complete response by cystectomy for persistent bladder cancer. Of these 17 patients 7 are alive, including 5 without disease, 4 to 41 months after treatment. The bladder appears to be responsive to this combination chemotherapy for invasive transitional cell carcinoma. This experience underscores the need for regular pathological re-staging of the bladder cancer in patients receiving chemotherapy.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Transitional Cell/drug therapy , Urinary Bladder Neoplasms/drug therapy , Antineoplastic Combined Chemotherapy Protocols/toxicity , Bone Neoplasms/secondary , Carcinoma, Transitional Cell/secondary , Carcinoma, Transitional Cell/therapy , Cisplatin/administration & dosage , Clinical Trials as Topic , Combined Modality Therapy , Female , Humans , Liver Neoplasms/secondary , Male , Methotrexate/administration & dosage , Middle Aged , Pelvic Neoplasms/secondary , Urinary Bladder Neoplasms/pathology , Urinary Bladder Neoplasms/therapy , Vinblastine/administration & dosageABSTRACT
Fifty-eight patients with metastatic transitional cell carcinoma of the urinary tract received cisplatin, methotrexate, and vinblastine (CMV) combination chemotherapy. Complete responses (CRs) were noted in 14 of the 50 (28%) evaluable patients and partial responses (PRs) in 14 patients for an overall response rate of 56% (95% confidence limits of 42% to 70%). The median duration of the 14 CRs was 9 months. Six of the 14 CRs (43%) remain in unmaintained remission from 6 + to 35 + months from onset of treatment. The median survival of evaluable patients receiving CMV was 8 months. Median survival for CRs was 11 months v 7 months for PRs (P less than .05) and 6 months for nonresponders. Renal and hematologic toxicities with this regimen were moderate. CMV is an effective regimen for patients with metastatic transitional cell carcinoma of the bladder. Prolonged disease-free survival may result from a CR to this regimen.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Transitional Cell/drug therapy , Urologic Neoplasms/drug therapy , Actuarial Analysis , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Carcinoma, Transitional Cell/blood , Carcinoma, Transitional Cell/secondary , Cisplatin/administration & dosage , Creatinine/blood , Dehydration/chemically induced , Drug Evaluation , Female , Hematologic Diseases/chemically induced , Humans , Male , Methotrexate/administration & dosage , Middle Aged , Nausea/chemically induced , Neoplasm Metastasis , Neoplasm Recurrence, Local , Urologic Neoplasms/blood , Vinblastine/administration & dosageABSTRACT
We studied the relationship between social class and prognosis in children with acute lymphoblastic leukaemia. Seventy children who were commencing on curative therapy, and who received central nervous system prophylaxis, were included in the study. Children from social classes 1 to 5 had a significantly better five-year survival rate and duration of first remission than children from social classes 6 and 7. There was no apparent difference either in the treatment given to the two groups or in the clinical and haematological parameters studied. A study of the causes of this difference in survival could lead to better over-all results in the treatment of childhood leukaemia.
Subject(s)
Leukemia, Lymphoid/mortality , Social Class , Black or African American , Age Factors , Australia , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Leukemia, Lymphoid/drug therapy , Male , Postoperative Complications/mortality , Prognosis , Socioeconomic Factors , White PeopleSubject(s)
Body Height , Leukemia, Lymphoid/epidemiology , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Social ClassABSTRACT
The endosperm proteins of the maize mutants, opaque-2, opaque-7, floury-2, brittle-2, and the double mutant of opaque-2 and brittle-2, were separated into five soluble fractions by the Landry-Moureaux method. As compared to their isogenic normal counterparts, the mutant endosperms had higher concentrations of albumins, globulins, and glutelin-3, and lower concentrations of prolamines. The combination of the opaque-2 and brittle-2 genes enhanced this difference. Although the four mutant genes are located on three different chromosomes, they exert a similar effect on endosperm protein composition. Five other starchmodifying mutants with high lysine content resemble the brittle-2 mutant in endosperm protein composition, when the gene is present either singly or combined with opaque-2. Therefore, the pattern of protein synthesis in all maize mutants with high lysine concentrations may be either identical or very similar. Because no synergistic effect on lysine concentration is obtained when floury-2 is combined with opaque-2, different pathways leading to reduced zein synthesis may exist in the floury and starch-modifying mutants with high lysine concentrations.